Results 231 to 240 of about 34,445,663 (284)

Severe Thrombocytopenia Associated With Glucagon‐Like‐1 Receptor Agonists (GPL‐1RA): A SONAR Report

Diabetes, Obesity and Metabolism, EarlyView.
Charles L. Bennett, Chadi Nabhan, Demir Uslu, Yogitha Dadi, David Aboulafia, Barbara Senger, Joseph Magagnoli, Kelvin Rojas, Gurdeep Singh, Linda Martin, Edward Smith, Samuel Ruder, Chien‐Hsiang Weng, Nikhil Uppal, Mia Lynch, James B. Bussel   +15 more
wiley   +1 more source

Glucagon like peptide-1 receptor agonist therapy and long-term renal outcomes after radical nephrectomy: a propensity-matched cohort analysis. [PDF]

Int Urol Nephrol
Ahmad NB, Kassim A, Manivasagam SS, Raman JD.   +3 more
europepmc   +1 more source

Effects of Glucagon-Like Peptide-1 Receptor Agonist on Bone Metabolism and the Expression of Insulin Receptor Substrate 1 in an Osteoporotic Rat Model. [PDF]

Int J Endocrinol
Ye Y, He YL, He J, Yang DY, Xia N.
europepmc   +1 more source

Apelin/APJ Signalling as a Potential Complementary Target for Glucagon-like Peptide-1 Receptor Agonist Therapy in Heart Failure. [PDF]

Card Fail Rev
Alfonso DM.
europepmc   +1 more source

The Glucagon-like Peptide-1 Receptor Agonist Era and Its Influence on Body-Contouring Referrals After Weight Loss in Appalachia. [PDF]

Plast Reconstr Surg Glob Open
Rahimpour A, Stuart I, Hyde JH, Roberts-Moore K, Price KR, Keefer JD, Persily A, Bown P, Barry R.   +8 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonist Use Is Associated With Improved Lung Function in Cystic Fibrosis‐Related Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Luke A. Ephraums, Edward R. Mignone, Kylie Lange, Ashlee Routley, Judith Morton, Emily Hopkins, Sally Chapman, Lucia Gagliardi, Michael Horowitz, Mahesh M. Umapathysivam   +9 more
wiley   +1 more source

Antecedent glucagon-like peptide-1 receptor agonist use and risk of sepsis-induced cardiomyopathy in type 2 diabetes: a United States real-world active-comparator cohort study. [PDF]

Front Pharmacol
Wu JY, Lee KW, Huang SC, Chang HY, Lin YM.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Glucagon-Like Peptide-1 Receptor Agonists

Surgical Clinics of North America
Highlights: Introduction Pharmacology Treatment Advantages/Disadvantages Therapeutic Considerations Monographs ...
Heather P. Whitley, Jennifer M. Trujillo
  +12 more sources

Overview of Glucagon-like Peptide-1 Receptor Agonists

Home Healthcare Now, 2015
Type 2 diabetes mellitus is an increasingly prevalent disease in the United States and globally. Multiple pharmacologic therapies are typically required over time to achieve and maintain target blood glucose levels. When first-line oral medications such as metformin (Glucophage) are not effective in achieving desired glycosylated hemoglobin (HbA1C ...
Laura, Steadman, Joan S, Grant, Lucinda J, Graven   +2 more
openaire   +2 more sources

Glucagon-like Peptide-1 Receptor Agonists

2021
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have been used to treat patients with type 2 diabetes mellitus (T2DM) since exenatide, the first GLP-1RA, was approved in 2005. GLP-1 is a peptide hormone secreted by L cells of the small intestine in response to nutrients.
Ja Young Jeon, Hae Jin Kim
openaire   +1 more source